Want to see HRTX full AI Analyst Report?
Net Sales by Segment
Breaks down Heron’s revenue by product line, therapeutic area, or geography to show which drugs and markets are driving growth or creating concentration risk. For a company with a small commercial portfolio, segment-level sales reveal whether recent launches, pricing, and reimbursement are gaining traction, highlight dependence on any single product or region, and flag where weaker demand or payer pressure could meaningfully affect top-line growth and margins.Sales mix is visibly shifting from legacy oncology and the wind‑down of SUSTOL toward high‑growth acute‑care products: ZYNRELEF and APONVIE are driving meaningful unit and account gains that offset CINVANTI’s modest softness. Management’s March rebound and the reaffirmed full‑year guidance imply Q1 weakness was seasonal/weather‑driven, not structural, but near‑term gross‑margin pressure from higher‑cost secondary CINVANTI supply will depress profitability until that inventory clears over the next two quarters; ZYNRELEF adoption and margin normalization are the key catalysts to watch.
Date | Cinvanti | Sustol | Zynrelef | Aponvie |
|---|---|---|---|---|
Jun 30, 2026 | $21.79M | $540.00K | $11.06M | $4.28M |
Mar 31, 2026 | $20.54M | $547.00K | $10.23M | $3.39M |
Dec 31, 2025 | $22.92M | $1.33M | $12.53M | $3.81M |
Sep 30, 2025 | $23.95M | $1.91M | $9.31M | $3.03M |
Jun 30, 2025 | $24.14M | $2.40M | $8.19M | $2.46M |
Mar 31, 2025 | $25.74M | $2.86M | $8.04M | $2.26M |
Dec 31, 2024 | $26.87M | $3.52M | $8.46M | $1.93M |
Sep 30, 2024 | $22.66M | $2.76M | $6.25M | $1.14M |
Jun 30, 2024 | $24.93M | $4.25M | $5.83M | $1.02M |
Mar 31, 2024 | $25.62M | $3.62M | $5.01M | $425.00K |